Advanced autologous plasma technology
Cutting-edge autologous plasma technology for faster, safer, and more effective tissue regeneration.
Enhancing tissue healing
across multiple specialties
Sovereign Medical, in partnership with BTI Human Technology, offers Endoret® (Plasma Rich in Growth Factors, PRGF®), a pioneering technology in regenerative medicine.
Endoret® (PRGF®) utilises the patient's own plasma, enriched with growth factors, to stimulate and accelerate tissue healing and regeneration. This autologous protein dynamic scaffold is versatile across various medical fields, including musculoskeletal (MSK), dermatology, and ophthalmology, providing tailored formulations to meet specific clinical needs.
Patient advantages of Rejoint
Use this space to promote the business, its products or its services. Help people become familiar with the business and its offerings, creating a sense of connection and trust. Focus on what makes the business unique and how users can benefit from choosing it.
Improved functionality
Significantly enhances limb function by restoring joint mobility.
Item Title
Decreases pain during movement, improving quality of life.
Item Title
As a bioabsorbable implant, RegJoint™ eliminates the need for removal surgeries.
Item Title
Describe the item here. Include important features, pricing and other relevant info.
Autologous and Biocompatible
As an autologous treatment, Endoret® (PRGF®) eliminates the risk of adverse reactions or incompatibility, promoting natural healing processes.
Reduced Inflammation and Pain
The formulation is free from leukocytes and inflammatory proteins, leading to decreased inflammation, pain, and tissue fibrosis.
Enhanced Healing
By stimulating cell proliferation and migration, it accelerates tissue regeneration, improving clinical outcomes.
Versatility
Allows for the preparation of specific formulations adapted to each tissue and clinical requirement, enhancing treatment efficacy.
Medical use cases
Endoret® (PRGF®) provides surgeons with a powerful, autologous regenerative solution that enhances healing, reduces complications, and improves patient outcomes across multiple specialties.
Offering a minimally invasive alternative to open and endoscopic carpal tunnel release.
Enhancing precision for surgeons specializing in hand and wrist conditions.
Streamlining outpatient procedures and optimizing patient throughput.
Providing an innovative solution for practices focusing on musculoskeletal and nerve-related disorders.
Technical specification
Endoret® (PRGF®) is an advanced plasma-rich growth factor (PRGF) technology, utilising a 100% autologous preparation process to isolate and concentrate platelets and bioactive proteins from the patient’s own blood. This system enables the controlled release of growth factors, optimising tissue regeneration while minimising inflammation.
The process involves a standardized centrifugation protocol, ensuring precise separation of blood components without leukocytes, reducing pro-inflammatory responses. Endoret® (PRGF®) is engineered to be highly versatile, with customisable formulations tailored for specific clinical applications, including liquid, fibrin matrix, and injectable gel forms.
The technology is biocompatible and sterile, meeting rigorous safety and regulatory standards, and can be seamlessly integrated into various surgical disciplines such as orthopedics, oral and maxillofacial surgery, dermatology, and sports medicine. With proven efficacy backed by scientific research, Endoret® (PRGF®) represents a cutting-edge approach to regenerative medicine, providing surgeons with a precise, reproducible, and patient-friendly solution
Clinical Evidence and Regulatory Compliance
Explore the technical research and clinical studies below to learn more about the science behind Endoret® (PRGF®).